Financial insights of PFE

MyFinsight

For the quarter ending 2025-09-28, PFE made $16,438M in revenue. $3,541M in net income. Net profit margin of 21.54%.

Unit: Million (M) dollars (except for numbers of shares and EPS)

Income Statement	2025-09-28	2025-06-29	2025-03-30	2024-12-31
Less net income attributable to noncontrolling interests	9	18	6	8
Provision/(benefit) for taxes on income	-216	141	-189	-421
Cost of sales	4,172	3,778	2,845	5,909
Selling, informational and administrative expenses	3,186	3,415	3,031	4,274
Research and development expenses	2,546	2,482	2,203	3,035
Acquired in-process research and development expenses	1,390	2	9	89
Amortization of intangible assets	1,223	1,211	1,211	1,359
Restructuring charges and certain acquisition-related costs	286	-18	678	750
Other (income)/deductionsnet	-517	-739	-953	-2,358
Total revenues	16,654	14,653	13,715	17,763
Income from continuing operations before provision/(benefit) for taxes on income	3,334	3,044	2,785	-10
Income from continuing operations	3,550	2,903	2,973	411
Discontinued operationsnet of tax	0	25	0	7
Net income before allocation to noncontrolling interests	3,550	2,928	2,973	418
Net income attributable to pfizer inc. common shareholders	3,541	2,910	2,967	410

Net income attributable to pfizer inc. common shareholders (in dollars per share)	0.62	0.51	0.52	0.07
Net income attributable to pfizer inc. common shareholders (in dollars per share)	0.62	0.51	0.52	0.07
Weighted-average shares--basic (in shares)	5,685,000,000	5,685,000,000	5,675,000,000	-11,326,000,000
Weighted-average shares--diluted (in shares)	5,714,000,000	5,706,000,000	5,710,000,000	-11,398,000,000